Drug – bio-affecting and body treating compositions – Conjugate or complex of monoclonal or polyclonal antibody,... – Conjugated via claimed linking group – bond – chelating agent,...
Patent
1980-01-28
1981-06-23
Brown, Johnnie R.
Drug, bio-affecting and body treating compositions
Conjugate or complex of monoclonal or polyclonal antibody,...
Conjugated via claimed linking group, bond, chelating agent,...
536 23, 536 29, 435184, A61K 3170, C07H 1702, C07H 1904
Patent
active
042750571
ABSTRACT:
Seven-membered heterocyclic nucleosides used to inhibit the deamination enzyme responsible for the inactivation of arabinosylcytosine (ara--C). Preferred nucleosides containing a seven-member aglycone are as follows: ##STR1## Preferred aglycones are as follows: ##STR2## Active components utilized against pyrimidine deaminases from mammalian tissues (mouse kidney and human liver) showed optimum advantage when compared with tetrahydrouridine (THU).
REFERENCES:
patent: 3462416 (1969-08-01), Hanze et al.
patent: 4163839 (1979-08-01), Umezawa et al.
Driscoll John S.
Liu Paul S.
Marquez Victor E.
Brown Johnnie R.
Hazel Blondel
Roberts, Jr. John S.
The United States of America as represented by the Department of
LandOfFree
Seven-membered ring compounds as inhibitors of cytidine deaminas does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Seven-membered ring compounds as inhibitors of cytidine deaminas, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Seven-membered ring compounds as inhibitors of cytidine deaminas will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2207637